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Editorial on the Research Topic
Novel Applications of Stereotactic Body Radiotherapy (SBRT)
The use of stereotactic body radiotherapy (SBRT) or stereotactic ablative radiotherapy (SABR) has
undergone a surge in enthusiasm around the world fueled by an improved understanding of the
radiobiology of high-fractional dose radiotherapy, technology development and increased
availability of high-precision delivery platforms, and the dissemination of published literature
through retrospective and prospective studies. Our current knowledge of SBRT/SABR has not only
expanded the use of this treatment approach in the historical and classic scenarios of brain and
spine SBRT/SABR and lung SBRT/SABR, but also led to new frontiers of clinical applications. In
this context, several recent studies were published within a special Research Topic specifically
focused on novel and unique applications of SBRT/SABR.
Greve et al. published a large retrospective analysis of patients treated with stereotactic
radiosurgery (SRS) for arteriovenous malformations with CT and MRI-based planning
approaches and without stereotactically-defined digital subtraction angiography over a 14-year
period. In total, this series evaluated the outcomes of 215 patients (53% treated with SRS as a first-
line treatment and 55% classified as Spetzler-Martin grade I-III) treated to a median dose of 18 Gy in
1 fraction to a median target volume of 2.4 cm3. Approximately 47% demonstrated complete
obliteration of the arteriovenous malformation, consistent with that observed in other series using
different treatment platforms, and supporting the use of this approach.
Although spine SRS/SBRT has been established as an effective treatment in the upfront
management of patients with spinal metastasis, Ehret et al. expand the evidence for treatment of
recurrent spine metastasis treated with SRS. In their study of 53 patients (initial treatment 36 Gy in
15 fractions treated to a median dose of 18 Gy in 1 fraction), the local control rate was 77% (Ehret
et al.). Furthermore expanding indications from metastatic sites to intramedullary lesions, Ehret
et al. report on 12 patients with WHO II/III spinal ependymomas treated to a median dose of 15 Gy
in 1 fraction with a local control rate of 84%. Together, these series support the role of spine SRS in
patients with extramedullary and intramedullary tumors.
Liu et al. reported on patients with hepatocellular carcinoma, and although radiotherapy was not
a particular focus of their study, demonstrate potential avenues for evidence development by
guiding patient selection for adjuvant treatment. They report on a series of 244 patients with
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hepatocellular carcinoma treated with narrow-margin (<1 cm
margin) or wide-margin (≥1 cm margin) resections (Liu et al.).
In total, post-operative recurrence was observed in 53% of
patients and not only was the risk of recurrence higher in
those treated with narrow-margin resections, the pattern of
recurrence was also different, with modest rates of marginal
recurrence (21 vs. 5%). These recurrence patterns were also
hypothesized to affect survival as those patients treated with
narrow margins also had reduced overall survival. Interestingly,
post-operative SBRT for patients with positive margins yielded
no marginal recurrences. In addition, Jiang et al. evaluated the
safety and efficacy of transarterial chemoembolization (TACE)
and SBRT for Barcelona Clinic Liver Cancer (BCLC) stage B
hepatocellular carcinoma. In their series, 57 patients were treated
to a dose of 20-50 Gy in 3-5 fractions; at a median follow-up of
42 months, the objective response rate was 86% and the disease
control rate was 97%. These results will help inform the clinical
practice of SBRT with consideration of post-operative SBRT in
patients at high-risk for local recurrence after surgery as well as
definitive treatment for those patients too high-risk for
invasive interventions.
SBRT for prostate cancer is now endorsed by national and
international treatment guidelines and Aghdam et al. describe
the demographic characteristics of patients treated with SBRT
over a 10-year period. Interestingly, in their analysis of 1,035
patients treated with prostate SBRT, travel distance did not
adversely affect use in African Americans, elderly patients, or
those from rural locations, supporting the broad adoption and
utilization of this treatment approach. Ultimately, the
convenience of SBRT over conventionally-fractionated
regimens allows for improved patient access to care.
The use of SBRT/SABR for patients with oligometastatic or
oligoprogressive disease is an area of intense study and recent
reports have supported the cost-effectiveness of this treatment
strategy (Mehrens et al.). Even in patients with pancreatic cancer
with liver-only oligometastatic disease, SBRT in addition to
chemotherapy appears safe and effective (Ji et al.). Yet,
treatment of lymph nodes with stereotactic radiotherapy
remains an understudied area. Burkon et al. reported on a
retrospective analysis of 90 patients treated with SBRT to
lymph nodes in the mediastinum, retroperitoneum, or pelvis.
The local control rate was modest at 69% at 3 years and the
median freedom from widespread dissemination was 14.6
months. Additional studies will evaluate the patterns of failure,
optimal dose and fractionation schedule, and patient selection
criteria for this treatment approach.
As we look towards the future of SBRT/SABR, the
introduction of innovative radiotherapy delivery approaches
represents a relatively nascent area of study. Feasibility studies
have begun to demonstrate the potential of particle therapy
delivery techniques, such as Spot-Scanning Proton Arcs (Liu
et al.), and future trials will incorporate these novel technologies
with increasing clinical indications.
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